Karyopharm to Be Delisted From Nasdaq After Chapter 11 Filing
Nasdaq notified Karyopharm Therapeutics on November 4 that it would delist the company's securities. Karyopharm will not appeal; trading is scheduled to be suspended November 11, with shares expected to move to OTC trading as KPTIQ. Its bankruptcy plan says existing equity securities are expected to have no value and provides no distribution to common or preferred stockholders.
On November 4, 2026, Nasdaq notified Karyopharm Therapeutics that it would delist the company's securities due to its Chapter 11 bankruptcy filing, citing specific Nasdaq listing rules. The company has decided not to appeal the decision. Trading of Karyopharm's shares is scheduled to be suspended at the opening of business on November 11, 2026, with the stock expected to transition to over-the-counter trading under the ticker symbol KPTIQ. The company's bankruptcy plan indicates that there will be no distribution to common or preferred stockholders, and it expects existing equity securities to have no value.